EPAS1 and nonpapillary renal cell carcinoma: To that end, we have examined the effects of PT2385, one of the HIF-2α antagonists that shows clinical efficacy in ccRCC (15), on morphological changes and hypoxic ventilatory control that are mediated by the carotid body.